PML–RARα ligand-binding domain deletion mutations associated with reduced disease control and outcome after first relapse of APL
暂无分享,去创建一个
H. Dombret | P. Fenaux | C. Gardin | C. Chomienne | R. Gallagher | E. Raffoux | B. Cassinat | C. Kelaidi | E. Schachter-Tokarz
[1] H. Dombret,et al. Treatment of Newly Diagnosed Acute Promyelocytic Leukemia (APL) in the Elderly: A Joint Analysis of the French -Belgian-Swiss and PETHEMA Groups. , 2009 .
[2] Carl W. Miller,et al. Hidden Abnormalities and Novel Classification of t(15;17) APL Based on Genomic Alterations. , 2007 .
[3] H. Dombret,et al. Treatment of newly diagnosed acute promyelocytic leukemia (APL): a comparison of French-Belgian-Swiss and PETHEMA results. , 2008, Blood.
[4] C. Sawyers,et al. Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency. , 2007, The Journal of clinical investigation.
[5] C. Bloomfield,et al. Frequent PML-RAR α Mutations in Relapse Patients on Acute Promyelocytic Leukemia (APL) Intergroup Phase III Trial C9710. , 2006 .
[6] H. Dombret,et al. Late first relapses in APL treated with all-trans-retinoic acid- and anthracycline- based chemotherapy: the European APL group experience (APL 91 and APL 93 trials) , 2006, Leukemia.
[7] C. Willman,et al. Relapse of acute promyelocytic leukemia with PML-RARα mutant subclones independent of proximate all-trans retinoic acid selection pressure , 2006, Leukemia.
[8] H. Dombret,et al. Late Relapses in APL Treated with ATRA and Anthracycline Based Chemotherapy: The European APL Group Experience (APL 91 and APL 93 Trials). , 2005 .
[9] Paola Fazi,et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.
[10] V. Lallemand-Breitenbach,et al. Pathways of retinoic acid- or arsenic trioxide-induced PML/RARα catabolism, role of oncogene degradation in disease remission , 2001, Oncogene.
[11] Jean-Paul Renaud,et al. Crystal structure of the RAR-γ ligand-binding domain bound to all-trans retinoic acid , 1995, Nature.